Few studies have addressed the differences between the two subcategories, or the clinical utility of distinguishing between them [4] [5] [6] [7] . Although there were clinical and pathological differences at the time of presentation, none of the studies have demonstrated differences in their outcomes. All previous studies based their findings on renal histopathology. Despite detailed descriptions by renal pathologists, the impact of renal biopsy on patient outcomes remains suboptimal. This is consistent with previous findings that different diseases, while leading to the same kidney histopathology, may have marked differences in response to treatment. For example, focal segmental glomerulosclerosis (FSGS) patients on renal biopsy can be steroid-responsive if the mutation is in the gene encoding phospholipase C-ε, but steroid-resistant if the mutation is in the gene encoding podocin [7, 8] . In addition, while idiopathic FSGS secondary to a circulating factor may be steroid responsive, FSGS that occurs secondary to hypertension, reflux and obesity tends to be steroid unresponsive [9] .
Given the disconnect between the pathogenic mechanism and the disease phenotype, a robust tool is needed to identify new pathogenic markers that can distinguish between two different kidney diseases that have different underlying etiologies, yet manifest with similar renal histopathology. This will be critical to identify new treatments as well as a guided treatment. Tissue proteomics has emerged as a powerful tool in mechanistic, diagnostic and therapeutic applications. In this study, we have chosen kidney tissue biopsy on the premise that the analysis will be conducted at the exact site of the disease pathology.
Using expression proteomics analysis, we compared global and segmental LN to normal tissues and antineutrophil cytoplasmic antibody (ANCA)-vasculitis. We further confirmed our findings by comparing the clinical, laboratory, renal and patient outcome between global and segmental LN in a large cohort of patients.
M AT E R I A L S A N D M E T H O D S
Tissue samples preparation Seventeen kidney tissue biopsies including IV-G n = 6, IV-S n = 5, ANCA n = 3 patients, and three normal kidneys with biopsy-proven diagnosis were subjected to proteomics analysis. Fresh-frozen tissues were carefully thawed and rinsed in phosphate-buffered saline with protease-inhibitor cocktails (benzamidine and phenylmethlysulfonyl fluoride). Approximately 20-50 µL of lysis buffer containing 7 M urea, 2 M thiourea and 4% sodium dodecyl sulphate, was added to each biopsy and agitated at 1000 RPM at room temperature for 3 h, followed by 13 000 RPM centrifugation for 15 min. Protein concentration was determined using protein-assay reagent (Bio-Rad, USA). Our institution's Research Advisory Council/ Research Ethics Committee approved the proposal.
Sample representativity, biological and analytical sample replicates We reported earlier that for successful proteome analysis, the quality and reproducibility of 2-DE gels largely correlates with adequate sample preparation procedures [10, 11] . In this study both histological and cytological evaluations of all samples were done to ensure sample representativity. Furthermore, the frozen tissue from each biopsy used for proteomic analysis was also examined histologically to show the pathologic global or segmental lesions seen on the paraffin sections. The minimum number of glomeruli in each biopsy was nine, and any sample below that was excluded from the analysis. Because of the relatively limited sample available for analysis, all biological samples were each run separately on a gel, and all gels across all samples were analyzed.
Electrophoresis, scanning and image analysis For each analyzed sample, 50 µg of total solubilized proteins (or 2-3 pooled samples in some cases) were dissolved in 350 µL volume of rehydration buffer and subjected to isoelectric focusing to a total of 45.5 kVh at 20°C using the PROTEAN IEF System (Bio-Rad). The second dimension was carried out in a 12% homogeneous Criterion™ XT gels, and proteins visualized by Sypro ruby staining gels were scanned at 50 µm resolution using Typhoon-Trio-Imager (GE). Data were analyzed by Progenesis SameSpots software (version 7.1.0, Nonlinear Dynamics, UK) for qualitative and quantitative differences.
Protein in gel-digestion and MALDI-TOF-MS analysis
For the purpose of protein identification, ∼500 µg proteins were loaded for micro preparative peptide mass fingerprinting. The observed differentially expressed protein spots on 2D gels were cut/picked from Instant Blue-stained gels (Expedeon™) by robotic Spot Cutter (Bio-Rad, Hercules, CA) into a 96-well microtiter plate for in-gel protein digestion carried out at 37°C for 4.5 h by Janus™ Automated MassPrep Station (Perkin Elmer). The extracted peptides (0.8 µL) were spotted with (0.8 µL) cyano-4-hydroxycinnamic acid matrix, 10 mg/mL (1/1 v/v CAN/0.1% aqueous TFA) onto MALDI Target plate. Mass Lynx Global Mass-Informatics v4.0 (Waters, Manchester, UK) was used for all automated data acquisition on a bench top MALDT-TOF Micro Mx (Waters). Protein Lynx Global Server was used for all automated data processing and database searching against a protein sequence database (SWISSPROT) using the PLGS 2.2 for protein identification (Waters).
Data processing and analysis
Quantitative differentially expressed protein spots datasets were generated using analysis of variance (ANOVA) analysis (P < 0.05) showing an >1.8-fold difference in the expression levels between sample groups. The pre-processed data were subjected to principal component analysis (PCA) available in the Progenesis SameSpots software program v 4.1.3 available at http://www.nonlinear.com.
Patients and data collection
We retrospectively identified all patients with the diagnosis of LN from 2003 to 2008. All renal biopsies were reviewed blindly and reclassified according to ISN/RPS 2003 classifications. We identified 78 patients with the diagnosis of LN Class IV and data extracted included, demographics, co-morbidities, laboratory, patient and renal survival. We defined patient survival as whether alive or not, irrespective of the cause of death. Renal failure was defined as whether the patient was put on dialysis or had received transplantation.
The response to the therapy includes complete remission, partial remission and treatment failure.
Complete remission was defined as urinary protein excretion <0.3 g/day, with normal urinary sediments (RBC < 3/HP, WBC < 5/HP), normal serum albumin and normal renal function.
Partial remission was defined as presence of any one of the following: decrease in serum creatinine to <130 µmol/L for patients with a baseline serum creatinine of ≥130 µmol/L but ≤260 µmol/L; decrease in serum creatinine by >50% for patients with a baseline serum creatinine of >260 µmol/L; and decrease in urinary protein excretion by >50%, and <3 g per 24-h with a serum albumin of ≥30 g/L and stable renal function. Baseline creatinine was defined as measurement at diagnosis.
Treatment failure was defined as any of the following: failure of the serum creatinine level to decrease to <130 µmol/ L for patients with a baseline serum creatinine of ≥130 µmol/L but ≤260 µmol/L; failure of the serum creatinine to improve by 50% for patients with a baseline serum creatinine of >260 µmol/L; urinary protein excretion >3 g per 24-h; failure of urinary protein excretion to improve by 50%; and serum albumin <30 g/L. The relapse of LN was defined as urinary protein excretion >1 g/day, active urinary sediments RBC > 5/HP or active disease approved by repeated renal biopsy.
Statistical analysis
We used SPSS 16.0 for statistical analysis. Quantitative data were expressed as mean ± SD, and median with range (minimum-maximum) and qualitative data were expressed as number and percentage. For comparison of clinical and pathological features of patients (quantitative data), Student's t-test, analysis of variance (ANOVA) and χ 2 test were used for qualitative data. Kaplan-Meier curves were used to analyze renal and patient's prognosis. Statistical significance was considered as P < 0.05.
R E S U LT S

Differential protein expression profiles in renal biopsies
Seventeen patients with kidney-proven biopsy were included in this analysis, (IV-G n = 6, IV-S = 5, ANCA, n = 3, and normal kidney n = 3). Whole-cell lysate of fresh-frozen renal biopsies were separated by 2DE ( Figure 1A ). Protein abundance was compared between groups to identify differences in protein expression profiles ( Figure 1B) . A PCA plot was applied using the 72 datasets of statistically differentially expressed protein spots across all gels to allow for objective classification and identification of outliers in samples. Global and segmental groups crossed over each other and clearly separated away from both normal biopsies and those with ANCA-associated vasculitis indicating that both IV-G and IV-S may represent a similar entity that is different from ANCA and normal renal biopsies ( Figure 1C ). However, there was a distinct classification when IV-G and IV-S was classified as one group and compared with ANCA-vasculitis and normal kidney tissue ( Figure 1D ).
Identification of differentially expressed proteins among the four groups
Due to limited material for micro-preparative analysis, only 42 protein spots corresponding to 28 protein species were successfully identified by matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF)/MS (Supplementary data S1). The functional characteristics of some of the identified proteins were listed in Supplementary data S4. Using Ingenuity Database program, these proteins were mapped and represented in multiple sub-signaling networks (Supplementary data S2). Several of these proteins were either directly or indirectly associated with pro-inflammatory factors and regulators such as interlukin-1, TGF-β and NFkB.
We then compared IV-G versus IV-S using the quantitative expression levels of the 28 identified differentially expressed proteins. IV-G and IV-S were similar in their expression levels of these proteins, supporting the notion that they are similar entities ( Figure 2A ). Furthermore, a post hoc analysis with Duncan's multiple range-test using the expression levels of these proteins did not show a statistical difference between IV-G and IV-S. However, when IV-G and IV-S were classified as one group and compared with ANCA-vasculitis and normal tissue, the differences were significant across nine proteins (Ezrin p81, serotransferin, cytokeratin 18, cytokeratin 19, alpha 1 antitrypsin, albumin, plasma glutathione peroxidase, 1433 protein epsilon and annexin V) (Supplementary data S3). There is no statistical difference between IV-G and IV-S, but when compared with ANCA or normal tissue, there are several differences among the expression level of these nine proteins ( Figure 2B ).
Validation of differentially expressed proteins by label-free LC/MS/MS
Results from 2-DE analysis are often limited to highly abundant Proteins while many proteins at low levels of expressions often elude detection. Hence, we have attempted to validate our observed results from 2-DE by subjecting newly collected samples including three normal, five IV-G and four ANCA kidney biopsy samples to high resolution liquid chromatography-tandem mass spectrometry analysis (LC/MS/ MS). The details of LC/MS/MS analysis is described in our recent publication [12] , and summarized in Supplementary Materials S5. Unfortunately we did not have access to new cases of IV-S. Interestingly, 84 significantly differentially expressed proteins were identified and distinctively discriminate between the three sample groups using PCA (Supplementary data S5). In addition to other differentially expressed proteins identified using LC/MS/MS, 16 of the 25 identified proteins from 2-DE analysis were also among those identified by LC/ MS/MS and both datasets shares similar expression patterns ( Figure 1D and Supplementary data S5). The proteins that have been identified in both 2-DE and LC/MS/MS analyses are indicated by asterisks in Supplementary data S4). The above results, demonstrated the potential of proteomics towards discovery of reliable diagnostic markers for LN and other kidney diseases.
Clinical and laboratory parameters of patients. To examine whether these data can be correlated with clinical outcome, a total of 78 patients were re-classified according to ISN/RPS 2003 LN classification [3] , Class IV-G, n = 50 and IV = S, n = 28. The patients' baseline characteristics and clinical presentations are shown in Table 1 . Patients with Class IV-G had a higher BMI compared with IV-S (26.4 ± 6.6 versus 21.5 ± 4.4, P = 0.001) and higher rate of alopecia (28 versus 3.6%, P = 0.009). On the other hand, patients with IV-S had a higher rate of hypertension compared with IV-G (46.4 versus 8%, P = 0.001). Previously published papers have indicated insignificant clinical differences between IV-S and IV-G at the time of the first biopsy. In addition, LN patients classified as IV-G tend to have higher blood pressure and other markers at baseline than patients with Class IV-S. Our analysis did not support a significant difference in BP outcome between IV-S and IV-G subclasses. We reviewed the blood pressure measurements as available in only 69 out of 78 patients at the beginning and at the end of the study for both groups and found that the mean blood pressure showed no significant difference between them. The rest of the clinical and demographic data listed showed no significant difference between the two groups. The patients' baseline serological data showed no statistical difference between the two groups ( Table 1) . Patients with IV-G had a heavier proteinuria at presentation when compared with IVS (5.5 ± 3.8 versus 2.6 ± 1.9 g, P = 0.009). However, when sub-group analyses were conducted using several t-tests, one would expect the Type I error rate to be inflated. We then attempted to control for Type I error rate using Bonferroni equation at 0.5 alpha level and found that there were no significant differences between the two groups at presentation in proteinuria, glomerular filtration rate or hypertension.
Renal histopathology. The IV-G group had more cases of glomeruli with cellular crescents compared with the IV-S group (56 versus 32.1%, P = 0.43). There is a trend toward more cases with severe acute tubular injury as well as severe vascular sclerosis but with no statistical significance ( Table 2) . . Statistically differentially expressed protein spots were used for the PCA (ANOVA, P < 0.05 and ≥1.8-fold-changes in expression levels). The analysis is based on quantitative expression levels of 72 protein spots across all gels in the form of a data table, with rows representing gels and columns representing spots to determine the principal axes of expression variation among samples. The expression of the dataset in each sample is transformed and plotted in multidimensional (in this case two-dimensional axes) components in space; the first principal component versus second principal components). This type of analysis allows an objective sample classification and identification of outliers in sample groups based on quantitative expression profiles. The plot was generated using Progenesis SameSpots 2-DE analysis software program version 4.1 (Nonlinear Dynamics).
O R I G I N A L A R T I C L E
P r o t e o m i c s a n a l y s i s i n l u p u s n e p h r i t i s
F I G U R E 2 : (A) A quantitative comparison of identified proteins expression between IV-G (blue) and IV-S (red). (B)
A quantitative comparison of identified proteins expression between IV-G (small chess board) and IV-S (large chess board) versus ANCA (horizontal crossbars) and normal kidney (vertical crossbars). The plot was generated using the expression dataset of some of the polypeptides that show similar expression profiles between IV-G and IV-S but differs significantly to ANCA and/or normal. Bars mark statistically significant differences among the sample groups. The histograms represent the means of normalized optical density of proteinexpression ± standard deviations. The lowest group means (broken bar) and highest group means (solid bars) were indicated, while *indicates statistical difference with P-value < 0.05 and **indicates P-value < 0.005).
Other histopathology data including wire loop and hyaline thrombi were not statistically different.
Treatment and outcome. There was no statistical difference in induction therapy, maintenance therapy or angiotensinconverting enzyme and angiotensin receptor blockers (ARBs) used between the two groups (Table 3) . More patients received cyclophosphamide as induction therapy in both groups while mycophenolate mofetil (MMF) was used more often as a maintenance therapy. A trend toward achieving complete remission was seen with IV-S compared with IV-G, but with no statistical significance. Relapse rate was also similar in both groups with a mean time to relapse of 18.4 ± 12.5 months for IV-G and 27.7 ± 19.6 months for IV-S, P = 0.755. The probability of renal survival and patient survival was not statistically different between the two groups as well (Figure 3) . 
Comparison of demographic, clinical and laboratory data between LN Class IV-G and IV-S
Patient's characteristics IV-G (n = 50) IV-S (n = 28) P-value 
O R I G I N A L A R T I C L E
D I S C U S S I O N
Classification of LN is very important in determining the appropriate therapy and the subsequent prognosis [13] [14] [15] .
There have been several attempts to standardize the definition and increase reproducibility in classifying LN [16] . The last one was made by ISN/RPS in 2003 where Class IV subcategories (global and segmental) were introduced. Whether this subdivision is important in terms of renal outcome and therapy guidance remains controversial. The introduction of such sub-classification came in part as a result of the findings by the LN collaborative study. The authors found that patients with severe segmental lesions involving >50% of the glomeruli (previously known as severe LN Class III, now equivalent to LN Class IV-S), had a worse 10-year outcome when compared with diffuse proliferative lesions (equivalent to LN Class IV-G). It was suggested that severe LN Class III should be reclassified and included in Class IV as a segmental group, as they may require a more aggressive form of therapy due to their worse prognosis.
Yokoyama et al. evaluated a smaller Japanese group that included 17 patients with Class IV-G and 6 patients with Class IV-S, with similar baseline clinical parameters in both groups. The authors found that the mean renal survival was not statistically significantly different between the two groups, however patients were not treated uniformly and those with LN IV-S were less likely to have received aggressive therapy [5] . Mittal et al. retrospectively studied 33 patients with Class IV LN, of whom 22 patients had Class IV-G, and 11, Class IV-S. There were no significant differences in age, sex and ethnicity. Although serum creatinine levels, diastolic blood pressures and proteinuria were higher in the IVG group, there was no difference in the outcome after an average follow-up of 38 and 55 months in the IV-S and IV-G groups, respectively [6] . Hill et al. evaluated 46 patients in a French population, including 15 LN IV-S, and 31 LN IV-G. Similar to Mittal et al., the IV-G group had higher serum creatinine and more proteinuria at baseline, however, renal survival based on the doubling of the serum creatinine at 10 years was similar in both groups [4] . In this study, a protocol biopsy was performed 6 months after the initial diagnosis and treatment. Thirty of the 46 patients converted to mesangial proliferative LN (Class II) after therapy while the remaining 16 patients biopsy showed Class IV with some inter-conversion in the subclasses. Interestingly, in the remaining 16 patients, the second biopsy showed transformation to IV-S in seven patients (all originally IV-G), six patients remained IV-G while three patients originally IV-S converted to IV-G, consistent with the idea that these two diseases constitute different spectrums of the same disease, rather than distinct entities [4] . In a Chinese population, Yu et al. studied a total of 172 patients with Class IV, with 152, IV-G and 20 IV-S cases. Consistent with the other studies, the IV-G had higher serum creatinine and worse proteinuria at presentation; however, patient survival and renal survival at ∼5 years of follow-up were similar in both groups [7] .
Our study has the largest number in the IV-S group reported to date. Consistent with all previous studies, the IV-G group had worse renal function and higher proteinuria at presentation. Unlike the lupus collaborative study and consistent with Mittal et al., Hill et al. and Yu et al., our study showed no difference in terms of patients or renal survival between the two groups. Moreover, our study is the first to use comparative proteomic analysis of IV-G and IV-S. We compared IV-G and IV-S to normal healthy tissue and to another autoimmune disease, ANCA-associated vasculitis. When compared with ANCA and normal controls, IV-G and IV-S had similar proteomic signature of the differentially expressed proteins. We acknowledge that the small sample size constitutes a limitation of this study, but the potential of 2-DE as a biomarker discovery tool has been greatly explored by several reported studies on clinical sample materials [17] [18] [19] [20] . Despite this caveat, we have applied multivariate data analysis for the differential changes and the data was validated using a non-gel, and label-free high resolution liquid chromatography-tandem mass spectrometry analysis (LC/MS/MS). The results of the two analyzed methods were complementary, and it was reassuring that the observed changes were truly of biological significance of phenotypic characteristics of tissues derived from LN patients.
Although, we did not explore any RNA analysis in this study, other studies have established that transcript levels do not necessarily correlate to protein levels and that the relationship of protein expression and RNA abundance is not linear [32] [33] [34] . Using the ingenuity pathway analysis database, we observed that the majority (60%) of our identified proteins were highly expressed at the protein level than previously reported mRNA abundance. While only 5 of 25 showed higher frequencies of expression at mRNA than protein, only one protein shared a similar expression pattern at both the protein and mRNA level. Thus, it might be necessary to assess changes at both the protein and mRNA levels in the same samples, especially to demonstrate whether or not both protein expression levels and mRNA abundance correlates well in the disease being studied. Interestingly, when these proteins were searched in Ingenuity database mapping pathways, several of them either directly or indirectly led to an interaction with interlukin-1b. Interlukin-1b has been associated with autoimmune diseases and inflammatory states [21] [22] [23] [24] . IL-1b antagonist is currently being used to treat severe rheumatoid arthritis [25, 26] . In patients with LN, IL-1b expression has been shown in monocytes, visceral epithelial cells and mesangial cells [27] . In experimental models of LN, IL-1b appears to be up regulated, which makes the IL-1b antagonist an attractive potential therapy [28] . However, data from animal models using IL-b antagonists are conflicting; this might be due in part to the different genetic background of animals used in these experiments [29, 30] . It is clear that there are clinical and pathological differences between the two groups at presentation but whether that translates into a different outcome remains questionable. Several studies have speculated a different pathogenesis between IV-G and IV-S where IV-S mimics a 'pauci-immune process' with less immune complex deposits and disease activity compared with IV-G [6, 31] . Whether the two groups represent a different pathogenic entity or are the same disease process presenting at different stages remains to be answered. However, Class IV-S might be an early stage of severe LN and can progress to IV-G without adequate therapy for several reasons. First, across all studies mentioned, IV-G is more common than IV-S, and clinical presentation is worse in terms of renal function and proteinuria at baseline. This might be due to delayed recognition of the disease and subsequently delayed renal biopsy leading to more cases at a later stage of Class IV with heavier proteinuria and worse renal function. Second, there were several inter-conversions between the subclasses IV-G and IV-S in renal biopsies arguing against a distinct pathogenesis and more for a different stage of the same disease with varying therapy response. Third, a trend towards a better outcome in Class IV-S was shown in our study. The French and Chinese studies might support an earlier stage of Class IV LN. Finally, the similar protein expression profiles of both groups compared with normal tissue and pauci-immune vasculitis further support the argument that we are dealing with the same disease entity.
These quantitative datasets are of interest as potential marker proteins and can offer an alternative complementary objective approach towards molecular classification of LN.
Based on all this data, one might question the benefit of this sub-classification to either predict prognosis or guide therapeutic decisions.
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Supplementary data are available online at http://ndt.oxford journals.org. 
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